3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
37
Carcinoma, Hepatocellular
14
Ovarian Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Stomach Neoplasms
3
Rectal Neoplasms
3
Neoplasm Metastasis
3
Glioblastoma
3
Recurrence
2
Liver Neoplasms
2
Diabetes Mellitus, Insulin-Dependent, 12
2
Brain Neoplasms
2
mCRC
1
Uterine Cervical Neoplasms
1
Unresectable Metastatic Colorectal Cancer
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Rectal Neoplasms Malignant
1
Proteinuria
1
Platinum-sensitive Relapsed Ovarian Cancer
1
Platinum-resistant Recurrent Ovarian Cancer (PROC)
1
Platinum-resistant Recurrent Ovarian Cancer
1
Osteosarcoma
1
Non-small Cell Lung Cancer Patients with Brain Metastases
1
Neutropenia
1
Neoplastic Cells, Circulating
1
NSCLC
1
Metastatic Colorectal Cancer With Left-sided Primary Tumor
1
Medulloblastoma
1
Interventions
Control Groups
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Unresectable Metastatic Colorectal Cancer
×
Bevacizumab
×
Clear all
NCT06642844
2024-10-15
PHARBEVACOL
University Hospital, Tours
Phase 3
Not yet recruiting
244 enrolled